Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative

The Australian Imaging Biomarkers and Lifestyle (AIBL) study is a longitudinal study of 1112 volunteers from healthy, mild cognitive impairment, and Alzheimer's disease (AD) populations who can be assessed and followed up for prospective research into aging and AD. AIBL aims to improve understanding of the pathogenesis, early clinical manifestation, and diagnosis of AD, and identify diet and lifestyle factors that influence the development of AD. For AIBL, the magnetic resonance imaging parameters of Alzheimer's Disease Neuroimaging Initiative (ADNI) were adopted and the Pittsuburgh compound B (11C‐PiB) positron emission tomography (PET) acquisition and neuropsychological tests were designed to permit comparison and pooling with ADNI data. Differences to ADNI include assessment every 18‐months, imaging in 25% (magnetic resonance imaging, 11C‐PiB PET but no fluorodeoxyglucose PET), more comprehensive neuropsychological testing, and detailed collection of diet and lifestyle data. AIBL has completed the first 18‐month follow‐up and is making imaging and clinical data available through the ADNI website. Cross‐sectional analysis of baseline data is revealing links between cognition, brain amyloid burden, structural brain changes, biomarkers, and lifestyle.

[1]  Colin L Masters,et al.  Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics , 2006, Journal of neurochemistry.

[2]  S Ourselin,et al.  β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia , 2010, Neurology.

[3]  Sébastien Ourselin,et al.  Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging , 2008, NeuroImage.

[4]  M A Pericak-Vance,et al.  Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. , 1993, Neurology.

[5]  R. Martins,et al.  ApoE genotypes in Australia: roles in early and late onset Alzheimer's disease and Down's syndrome , 1995, Neuroreport.

[6]  B. Ainsworth,et al.  International physical activity questionnaire: 12-country reliability and validity. , 2003, Medicine and science in sports and exercise.

[7]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.

[8]  C. Rowe,et al.  Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. , 2010, Journal of Alzheimer's disease : JAD.

[9]  E. Anderson.  Hudson et al. , 1977 .

[10]  C. Rowe,et al.  Relationship between atrophy and β‐amyloid deposition in Alzheimer disease , 2010, Annals of neurology.

[11]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[12]  J. Hardy,et al.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.

[13]  C. Jonker,et al.  Are memory complaints predictive for dementia? A review of clinical and population‐based studies , 2000, International journal of geriatric psychiatry.

[14]  H. Wiśniewski,et al.  Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease , 2000 .

[15]  F. Liu,et al.  Association of Apolipoprotein M Gene Polymorphisms with Ischemic Stroke in a Han Chinese Population , 2011, Journal of Molecular Neuroscience.

[16]  Amanda J. Patterson,et al.  The Anti Cancer Council of Victoria FFQ: relative validity of nutrient intakes compared with weighed food records in young to middle‐aged women in a study of iron supplementation , 2000, Australian and New Zealand journal of public health.

[17]  C. Rowe,et al.  The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.